Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05217940 · ClinicalTrials.gov registry record · NA

Screening Women With Prior HPV for Anal Neoplasia

A NA study of HPV-related Lower Genital Tract Neoplasias and HPV-related Anal Neoplasias, sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
NA
Development phase
300
Enrollment target
3
Study locations

NCT05217940 is a NA study of HPV-related Lower Genital Tract Neoplasias and HPV-related Anal Neoplasias that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 300 participants. The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05217940, a NA study of HPV-related Lower Genital Tract Neoplasias and HPV-related Anal Neoplasias, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
NA
Development phase
300 participants
Enrollment target
3
Study locations

Study Summary

The goal of this single arm trial is to prospectively evaluate screening methods for anal cancer precursors in HIV uninfected women with a history of lower genital tract neoplasias and cancers.

Interventions

  • DIAGNOSTIC_TEST Diagnostic tests for anal cancer screening

Study Locations (3)

New York

  • Icahn School of Medicine at Mount Sinai - New York

South Carolina

  • Medical University of South Carolina - Charleston

Texas

  • University of Texas M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2022-03-02
Est. Completion 2027-01
Phase NA

What the Registry Record Tells You About NCT05217940

The ClinicalTrials.gov registry entry for NCT05217940 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with HPV-related Lower Genital Tract Neoplasias appearing as the primary indexed condition, and to 1 intervention - of which Diagnostic tests for anal cancer screening is the first listed.

NCT05217940 reports 3 study locations spanning 3 distinct geographic areas - top geographies include New York, South Carolina, Texas.

Frequently Asked Questions

What is clinical trial NCT05217940 about?

NCT05217940 is a clinical study titled "Screening Women With Prior HPV for Anal Neoplasia". The goal of this single arm trial is to prospectively evaluate screening methods for anal cancer precursors in HIV uninfected women with a history of lower genital tract neoplasias and cancers.

What is the current status of trial NCT05217940?

This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2022-03-02. Estimated completion is 2027-01.

What conditions does trial NCT05217940 study?

This clinical trial studies the following conditions: HPV-related Lower Genital Tract Neoplasias, HPV-related Anal Neoplasias, Early Stage Lower Genital Tract Cancers.

What interventions are being tested in trial NCT05217940?

The interventions under investigation include: Diagnostic tests for anal cancer screening (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05217940?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05217940 being conducted?

This trial has 3 study locations across New York, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.